Actively Recruiting
Characterization of Heart Failure With Preserved Ejection Fraction
Led by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Updated on 2024-02-05
500
Participants Needed
1
Research Sites
730 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goals of this research will be to define some of the mechanisms underlying the progression and complications of heart failure (HF) with preserved left ventricular ejection fraction (HFPEF) Aim 1: to evaluate the differences in cardiac structure, function and fibrosis markers through the spectrum of HF stages in order to deepen the understanding of the pathophysiology driving HF progression. Aim 2: to define the mechanisms by which HF risk factors, such as hypertension, diabetes, obesity, and renal insufficiency, interact with age to increase HF risk, and to evaluate the role of precipitating factors such as myocardial ischemia, atrial fibrillation in HFPEF. Aim 3: to determine prognostic factors in HFPEF patients, by following these patients over time. Accordingly the investigators will correlate baseline data (echocardiographic, MRI or biomarkers) with incident cardiovascular events and determine whether these measures provide incremental prognostic information beyond clinical characteristics.
CONDITIONS
Official Title
Characterization of Heart Failure With Preserved Ejection Fraction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 99 years
- Patients with typical symptoms and signs of heart failure
- New York Heart Association (NYHA) functional class II or higher
- N-terminal pro-B type natriuretic peptide (NT-proBNP) level above 350 pg/mL or hospitalization for heart failure within the last 12 months
- Left ventricular ejection fraction (LVEF) of 50% or higher with signs of diastolic dysfunction (e.g., left atrial volume > 34 ml/m2, E/e' ratio > 14, tricuspid regurgitation velocity > 2.8 m/s, septal e' velocity < 7 cm/s, or lateral e' velocity < 10 cm/s)
- Controls without a history of heart failure or previous cardiovascular disease will also be recruited
You will not qualify if you...
- Severe valvular heart disease
- Infiltrative or hypertrophic cardiomyopathy
- Acute coronary syndrome within the previous 30 days
- Chronic obstructive pulmonary disease GOLD stage 3 or 4
- Congenital heart disease
- Pericardial disease
- Terminal renal failure (eGFR < 15 mL/min/1.73m2) or need for dialysis
- Atrial fibrillation with a ventricular response over 140 bpm
- Severe anemia (hemoglobin < 8 g/dL)
- Liver dysfunction
- Active or evolving cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cliniques universitaires Saint Luc
Brussels, Belgium
Actively Recruiting
Research Team
A
Anne-Catherine Pouleur
CONTACT
A
Anne Catherine Pouleur
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here